Core Viewpoint - The company, Hailianxun (300277.SZ), has completed the share swap absorption merger with Hangzhou Turbine Power Group Co., Ltd. and plans to change its name and securities abbreviation to "Qilun Technology" to align with its future business strategy [1] Group 1 - The share swap related to the merger has been completed [1] - The name change and abbreviation adjustment are based on the company's strategic development needs [1] - The new company name will match the company's future main business and will not adversely affect its operations or harm the interests of the company and its shareholders [1]

格隆汇2月11日丨广康生化(300804.SZ)公布，特定股东共青城华拓至盈贰号投资合伙企业（有限合伙） （简称"华拓至盈贰号"）、深圳市华拓至远叁号投资企业（有限合伙）（合称"华拓至远叁号"）以及共 青城瑞宏凯银壹号股权投资基金合伙企业（有限合伙）（简称"瑞宏凯银壹号"）计划自本公告披露之日 起三个交易日后的三个月内，通过集中竞价和大宗交易方式减持公司股份。其中，华拓至盈贰号和华拓 至远叁号计划合计减持不超过131.98万股，即不超过公司总股本的1.7835%；瑞宏凯银壹号计划减持不 超过198万股，即不超过公司总股本的2.6757%。 ...

Core Viewpoint - The company Baiyunshan (600332.SH) announced that its subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its injectable penicillin sodium (0.96g, 1.6 million units), which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1] - Penicillin is the preferred drug for infections such as hemolytic streptococcal infections, pneumococcal infections, and infections caused by penicillinase-negative staphylococci [1] - The drug is also effective against anthrax, tetanus, gas gangrene, syphilis (including congenital syphilis), leptospirosis, relapsing fever, diphtheria, and in combination with aminoglycosides for treating viridans streptococcal endocarditis [1]

格隆汇2月11日｜格林美(002340.SZ)公告称，公司于2026年2月11日召开董事会审议通过议案，决定终 止全资下属公司PT INDONESIA QINGMEI ENERGY MATERIALS的增资扩股实施股权改组暨关联交易 事项。该决定是基于现阶段内外部形势的变化，并审慎评估了本次交易实施后被动形成财务资助带来的 风险。终止后，目标公司仍为公司全资下属公司，不会形成公司的对外财务资助。该决定有利于保障公 司业务的完整性及资金的安全性，维护公司和广大投资者利益。 ...

格隆汇2月11日丨首旅酒店(600258.SH)公布，公司间接全资控股子公司如家酒店连锁(中国)有限公司 （以下简称"如家（中国）"）与本公司控股股东北京首都旅游集团有限责任公司（以下简称"首旅集 团"）及关联企业共同参股投资的北京环汇置业有限公司（以下简称"环汇置业"）签署了《商业房屋租 赁合同》，租赁期10年，其中租赁期租金含税总金额为29,859.071684万元；物业费含税总金额为 2,415.469927万元，两项合计含税总金额为32,274.541611万元。另，租赁保证金506.74572万元。根据多 品牌集群方案及其工程以及配套设施设备的建设规划，后续拟投资10,818.6万元用于装修和运营，打造 建国铂萃、建国璞隐、建国扉缦等三大核心品牌酒店。（以下简称"项目"）。项目预计总金额为 43,599.887331万元。 ...

格隆汇2月11日丨漳州发展(000753.SZ)公布，公司全资子公司福建漳发建设有限公司（简称漳发建设） 就漳州市常山竹港溪防洪排涝提升改造工程（一期）设计施工总承包（EPC）—生态修复工程专业分包 （标段一）与福建大农景观建设有限公司（简称大农景观）签署《建设工程施工专业分包合同》，合同 价款为2,493.0388万元。鉴于大农景观为公司控股股东福建漳龙集团有限公司（简称漳龙集团）的下属 企业，上述交易构成关联交易。 ...

经公司第二届董事会提名委员会进行任职资格审查后，公司于2026年2月11日召开第二届董事会第二十 二次会议，审议通过了《关于聘任公司总经理的议案》，同意聘任陈健旭先生担任公司总经理，任期自 本次董事会审议通过之日起至第二届董事会任期届满之日止。 格隆汇2月11日丨南新制药（维权）(688189.SH)公布，公司董事会于近日收到张世喜先生提交的书面辞 职报告，张世喜先生因工作调整原因申请辞去公司总经理职务。根据《公司法》《公司章程》的有关规 定，张世喜先生的辞职报告自送达董事会之日起生效。辞职后，张世喜先生仍担任公司董事、董事长、 董事会战略委员会召集人职务。 ...

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) aims to optimize its asset structure and improve the quality of asset operations by transferring part of its accounts receivable through a public listing [1] Group 1: Asset Transfer Details - The company plans to transfer accounts receivable with a total book balance of 489.784 million yuan as of the assessment benchmark date of September 30, 2025 [1] - Bad debt provisions amount to 459.7945 million yuan, resulting in a book value of 29.9895 million yuan for the receivables being transferred [1] - The asset transfer is expected to enhance the company's operational development and protect the legal rights of the company and all shareholders [1] Group 2: Transaction Process - The transaction will be conducted through a public listing, and no transaction agreement has been signed yet [1] - It is currently unclear whether the transaction will constitute a related party transaction [1] - If the determined buyer through the public listing process is a related party, the company will follow the necessary review procedures for related party transactions [1]

Core Viewpoint - The company, through its subsidiaries, is participating in a national centralized procurement process for pharmaceuticals, which could enhance its market share and brand influence if selected products are confirmed and contracts are signed [1] Group 1: Company Participation - The company’s wholly-owned subsidiaries and a controlling subsidiary are involved in the national centralized procurement for expiring drug agreements [1] - The procurement office announced the proposed selection results for the procurement on February 10, 2026 [1] Group 2: Potential Impact - If the proposed selected products are confirmed and contracts are signed, it will help the company expand sales of related products [1] - The successful procurement will ensure that medical institutions prioritize the selected drugs, which is expected to positively impact the company's future operating performance [1]

Core Viewpoint - Huatai Technology (603679.SH) announced a share reduction by one of its actual controllers, Wang Shaorong, through block trading, resulting in a change in shareholding percentage due to capital changes from convertible bond conversions [1] Group 1 - Wang Shaorong reduced her shareholding by 1.916 million shares between February 6, 2026, and February 10, 2026 [1] - Following the reduction and the impact of convertible bond conversions, the combined shareholding percentage of Wang Shaorong and her concerted parties decreased from 33.80% to 32.55% [1] - The change in equity holding triggered a shift that touched the 1% threshold [1]